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Abstract
Alzheimer’s disease (AD) and mild cognitive impairment (MCI) are of great current research interest. While there is no
consensus on whether MCIs actually ‘‘convert’’ to AD, this concept is widely applied. Thus, the more important question is
not whether MCIs convert, but what is the best such definition. We focus on automatic prognostication, nominally using only
a baseline brain image, of whether an MCI will convert within a multi-year period following the initial clinical visit. This is not
a traditional supervised learning problem since, in ADNI, there are no definitive labeled conversion examples. It is not
unsupervised, either, since there are (labeled) ADs and Controls, as well as cognitive scores for MCIs. Prior works have
defined MCI subclasses based on whether or not clinical scores significantly change from baseline. There are concerns with
these definitions, however, since, e.g., most MCIs (and ADs) do not change from a baseline CDR=0.5 at any subsequent visit
in ADNI, even while physiological changes may be occurring. These works ignore rich phenotypical information in an MCI
patient’s brain scan and labeled AD and Control examples, in defining conversion. We propose an innovative definition,
wherein an MCI is a converter if any of the patient’s brain scans are classified ‘‘AD’’ by a Control-AD classifier. This definition
bootstraps design of a second classifier, specifically trained to predict whether or not MCIs will convert. We thus predict
whether an AD-Control classifier will predict that a patient has AD. Our results demonstrate that this definition leads not
only to much higher prognostic accuracy than by-CDR conversion, but also to subpopulations more consistent with known
AD biomarkers (including CSF markers). We also identify key prognostic brain region biomarkers.
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Introduction
The dementing illness Alzheimer’s disease (AD), and the tran-
sitional state between normal aging and AD referred to as mild
cognitive impairment (MCI) continue to be widely studied.
Individuals diagnosed with MCI have memory impairment, yet
without meeting dementia criteria. Annually&10–15% of people
with MCI are diagnosed with AD [1]. Moreover, prior to
symptom onset, brain abnormalities have been found in people
with MCI, as ascertained by retroactive evaluation of longitudinal
MRI scans [2]. There is no consensus on whether MCI patients
actually ‘‘convert’’ to AD. First, some MCI patients may suffer
from other neurodegenerative disorders (e.g., Lewy body demen-
tia, vascular dementia and/or frontotemporal dementia). Second,
it is possible that all other MCI patients already have AD, but at a
preclinical stage. AD diagnosis itself may not be considered
definitive without e.g. confirming pathologies such as the amyloid
deposits detectable at autopsy. Regardless of whether MCI
patients truly ‘‘convert’’ to AD or not, the concept of MCI-to-
AD conversion has been widely applied, e.g. [3,4,5,6,7] and is
utilitarian – defining MCI (converter and nonconverter) subgroups
allows use of statistical group difference tests and machine learning
methods to help identify early disease biomarkers and to build
models for predicting disease progression. For these purposes, the
more important question is not whether MCIs convert, but rather
what is the best such definition.
Accordingly, here we focus on the following Aim: automatic
prognostication, (nominally) using only a baseline brain scan, of
whether an MCI individual will convert to AD within a multi-year
(three year) period following an initial (baseline) clinical visit. Our
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based on the ADNI database, which followed participants for a
period of up to three years. (Data used in preparation of this article
were obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database adni.loni.ucla.edu. As such, the
investigators within the ADNI contributed to the design and
implementation of ADNI and/or provided data but did not
participate in analysis or writing of this report. A complete listing
of ADNI investigators can be found at: http://adni.loni.ucla.edu/
wp-content/uploads/how_to_apply/ADNI_Authorship_List.pdf).
While only image voxel-based features are evaluated here for
use by our classifier, our framework is extensible to incorporating
other baseline visit clinical information (e.g. weight, gender,
education level, genetic information, and clinical cognitive
scores such as the Mini Mental State Exam (MMSE)) into the
decisionmaking. Moreover, our approach can also incorporate the
recent, promising cerebrospinal fluid (CSF) based markers [8].
However, as this requires an invasive spinal tap, we focus here on
image scans, which are routinely performed for subjects with MCI.
We do not hypothesize that, within ADNI, there are actually
two subclasses of MCI subjects when evaluated over the very long
term – those that (eventually) convert to AD, and those that do
not. Even if an overwhelming majority of MCI subjects will
eventually convert, identifying the subgroup likely to convert within
several years has several compelling utilities: 1) early prognosis, to
assist family planning; 2) facilitating group-targeted treatments/
drug trials; 3) we identify key prognostic brain ‘‘biomarker’’ regions,
i.e. those found to be most critical for accurately discriminating our
‘‘converter’’ and ‘‘nonconverter’’ groups. These regions may shed
light on disease etiology.
Distinguishing AD converters from nonconverters is a binary
(two-class) classification problem. Moreover, it may appear this
classification problem can be directly addressed via supervised
learning methods [9]. However, it is in fact an unconventional
problem, lying somewhere between supervised classification and
unsupervised classification (clustering), and thus requiring a unique
approach. To appreciate this, consider the ADNI cohort of MCI
individuals. ADNI consists of clinical information and image scans
on hundreds of participants, taken at six-month intervals for up to
three years. A clinical label (AD, MCI, or Control) was assigned to
each participant at first visit. Clinicians derive the AD/MCI/
Control label based on multiple criteria, which may include
Clinical Dementia Rating (CDR), whose possible values are:
0=none, 0.5=questionable, 1=mild, 2=moderate, 3=severe. Even
though a probable AD definition based on CDR and MMSE scores
and NINCDS/ADRDA criteria has been used (e.g. [10,7]) to
provide follow-up assessment for MCI patients, this is strictly a
clinically driven definition, based on a clinical rating (CDR) and a
cognitive score (MMSE) whose difficulties will be pointed out
shortly. This is not a definitive (autopsy-based) determination of
AD, nor is it a definition based on physiological brain changes.
Even if the probable AD definition has very high specificity, it may not
be sufficiently sensitive, i.e. there may be patients who are
undergoing significant physiological brain changes consistent with
conversion, yet without clinical manifestation.
Accordingly, we will approach the conversion problem from a
perspective as agnostic and unbiased as possible, and simply state
that it is not definitively known which MCI participants in ADNI
truly converted to AD within three years. In conventional
supervised classifier learning, one has labeled training examples,
used for designing the classifier, and labeled test examples, used to
estimate the classifier’s generalization accuracy. For predicting
whether MCI participants in ADNI convert to AD, we in fact
have neither. Thus, our problem is not conventional supervised
learning. On the other hand, consider unsupervised clustering [9].
Here, even if one knows the number of clusters (classes) present,
there is no prior knowledge on what is a good clustering – one is
simply looking for underlying grouping tendency in the data.
Clearly, our problem does not fit unsupervised clustering, either –
while we have no ground-truth labeled MCI converter/noncon-
verter instances per se, 1) there are two designated classes of
interest (converter and nonconverter); and 2) there are known class
characteristics – conversion to AD should, plausibly, mean that: (i)
a clinical measure such as CDR or a cognitive measure has
changed and/or (ii) there are changes in brain region features or in
CSF biomarkers more characteristic of AD subjects than normal/
healthy subjects. Note that in ADNI we do have plentiful labeled
AD and normal/healthy (Control) examples to help assess ii).
Based on the above, MCI prognosis is an interesting and novel
problem, lying somewhere between supervised and unsupervised
classification. The crux of this problem is to craft criteria through
which meaningful MCI subgroups can be defined, well-capturing
notions of ‘‘AD converter’’ and ‘‘nonconverter’’. To help guide
development and evaluation of candidate definitions, we state the
following three desiderata: 1) The proposed definition of AD
converter should be plausible and should exploit the available,
relevant information in the ADNI database (e.g. image data,
labeled AD and Control examples, and clinical information). To
appreciate 1), note that the MCI population could be dichoto-
mized in many ways, e.g. by height, and there might be significant
clustering tendency with respect to height, but such a grouping is
likely meaningless for MCI prognosis; 2) A classifier trained based
on these class definitions should generalize well on test data (not used
for training the classifier) – this quantifies how accurately we can
discriminate the classes that we have defined. Equivalently, it tells
us whether the features we are using are adequate for well-
discriminating the classes we define. If we create what we believe
to be good definitions, but ones that cannot be accurately
discriminated, that would not be useful clinically; 3) The class
definitions should be validated using known AD conversion
biomarkers ( i.e., external measures) such as measured changes
from baseline in volumes or final visit volumes of brain regions
known to be associated with the disease [11], CSF biomarkers
[12], and cognitive test scores (such as the clinical MMSE
measure).
Prior Related Work
Several prior works, e.g. [4,5,13], defined converter and
nonconverter classes solely according to whether the baseline visit
CDR score of 0:5 rose or stayed the same over all visits. Change in
CDR has also been used as surrogate ground-truth for cognitive
decline in a number of other papers, e.g. [14,6]. While CDR gives
a workable conversion definition, it should be evaluated with
respect to the three desiderata above. We will evaluate 2) and 3) in
the sequel. With respect to 1), one should challenge a CDR-based
conversion definition. First, CDR is not an effective discriminator
between the AD and MCI groups, i.e. there is very significant AD-
MCI overlap, not only with respect to CDR=1 but even 0.5 – for
ADNI, the majority of the hundreds of AD subjects used in our
experiments start (at first visit) at CDR=0.5 and stay at 0.5 at all
later visits; likewise, nearly all MCI subjects start at 0.5, with a
large majority of these also staying at 0.5 for all visits. This latter
fact further implies difficulties in finding an adequate number of
conversion-by-CDR subjects in ADNI, both for accurate classifier
training and test set evaluation. For the even more stringent
probable AD definition (meeting MMSE and NINCDS/ADRDA
criteria, in addition to CDR changing from 0.5 to 1) there are
necessarily even fewer MCI converters for classifier training and
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conversion definition ignores the (rich) phenotypical information in
an MCI subject’s image brain scans and does not exploit the
labeled AD and normal/healthy (Control) examples in ADNI.
These prior works do treat features derived from brain scans as the
covariates (the inputs) used by the classifier/predictor. However, we
believe the MCI brain scans can themselves be used, in
conjunction with the labeled AD and Control examples, to help
define more accurate surrogate ground-truth.
Previous work has demonstrated that structural MRI analysis is
useful for identifying AD biomarkers in individual brain regions
[15,16,17] – e.g., cortical thinning [18,19], ventricle dilation and
gaping [14,3,20], volumetric and shape changes in the hippocam-
pus and entorhinal cortex [21,22,23], and temporal lobe shrinkage
[24]. It is important to capture interaction effects across multiple
brain regions [2,5,25,13]. did jointly analyze voxels (or regions)
spanning the entire brain and did build classifiers or predictors.
Moreover, as part of their work [13], investigated prediction of
future decline in MCI subjects working from baseline MRI scans,
which is the primary subject of our current paper. However, there
are several limitations of these past works. First, all these studies
used the previously discussed CDR and cognitive measures such as
MMSE, which has been described as noisy and unreliable, as
the ground-truth prediction targets for classifier/regressor training.
In [14], the authors state: ‘‘Cognitive assessments are notori-
ously variable over time, and there is increasing evidence that
neuroimaging may provide accurate, reproducible measures of
brain atrophy.’’ Even in [13], where MMSE was treated as the
measure of decline and the ground-truth regression target, the
authors acknowledged that ‘‘individual cognitive evaluations are
known to be extremely unstable and depend on a number of
factors unrelated to…brain pathology.’’ Such factors include sleep
deprivation, depression, other medical conditions, and medica-
tions. Even though MMSE is widely used by clinicians, these
comments (even if not universally accepted), do indicate MMSE
by itself may not be so reliable in quantifying the disease state.
Moreover, while [13] did build predictors of future MMSE scores
working from baseline scans, this was not a main focus of their
paper – their paper focused on predicting the current score. Their
prognostic experiments involved a very small sample size (just 26
participants from the ADNI database). Accordingly, it is difficult to
draw definitive conclusions about the accuracy of their prognostic
model and their associated brain biomarkers. The main reason the
authors chose such a small sample was, as the authors state: ‘‘A
large part of…ADNI…are from patients who did not display
significant cognitive decline…[these] would overwhelm the
regression algorithm if..used in the…experiment.’’ While this
statement (with cognitive decline measured according to MMSE)
may be true, that does not mean many of those excluded ADNI
subjects are not experiencing significant physiological brain
changes/atrophy. The novel approach we next sketch is well-
suited to identifying MCI subjects undergoing such changes.
Our Neuroimaging-Driven, Trajectory-Based Approach
Here, we propose a novel approach for prognosticating putative
conversion to AD driven by image-based information (and
exploiting AD-Control examples), rather than by a single, non-
image-based, weakly discriminating clinical measurement such as
CDR. Our solution strategy is as follows. We first build an
accurate image-based Control-AD classifier ( i.e., using AD and
Control subjects, we build a Support Vector Machine (SVM)
classifier) (Vapnik, 1998). We then apply this classifier to a training
population of MCI subjects – separately, for each subject visit, we
determine whether the subject’s image is on the AD side or the
Control side of the SVM’s fixed (hyperplane) decision boundary.
In addition to a binary decision, the SVM gives a ‘‘score’’ –
essentially the distance to the classifier’s decision boundary. Thus,
for each MCI subject, as a function of visits, we get an image-
based ‘‘phenotypical’’ score trajectory. We fit a line to each
subject’s trajectory and extend the line to the sixth visit if the sixth
visit is missing. We can then give the following trajectory-based
conversion definition: if the extended line either starts on the AD side
or crosses to the AD side over the six visits, we declare this person
a ‘‘converter-by-trajectory’’. Otherwise, this person is a ‘‘non-
converter-by-trajectory’’. (A very small percentage of the MCI
population, in our experiments often 1% and not exceeding 5%,
may unexpectedly start on the AD side and cross to the Control
side. We treat these individuals as outliers and omit them from our
experiments.) In this fashion, we derive ground-truth ‘‘converter’’
and ‘‘nonconverter’’ labels for an (initially unlabeled) training MCI
population. These (now) labeled training samples bootstrap the
design of a second SVM classifier which uses only the first-visit
training set MCI images and is trained to predict whether or not
an MCI patient is a ‘‘converter-by-trajectory’’. Essentially, this
second (prognostic) classifier is predicting whether, within three
years, an AD-Control classifier will predict that a patient has AD.
Via these two classifier design steps, we thus build a classification
system for our (unconventional) pattern recognition task.
SVMs are widely used classifiers whose accuracy is attributed to
their maximization of the ‘‘margin’’, i.e. the smallest distance from
any training point to the classification boundary. Since the SVM
finds a linear discriminant function that maximizes margin, a sig-
nificant change in score is generally needed to cross from the
control side to the AD side, which is thus suggestive of conversion
from MCI to AD. This is the premise underlying our approach.
The main contributions of our work are: 1) a novel machine
learning framework for prognostication falling somewhere be-
tween traditional supervised and unsupervised learning; 2) a novel
image-based prognosticator of MCI-to-AD conversion that we will
demonstrate to achieve both better generalization accuracy and
much higher correlation with known brain region biomarkers and
with CSF-based markers than the CDR-based approach; 3)
Identification of the brain regions most critical for accurately
discriminating between our ‘‘converter’’ and ‘‘nonconverter’’
groups, via application of margin-based feature selection (MFE)
[26] to brain image classification, and demonstration of MFE’s
better performance than the well-known RFE method [27] on this
domain.
Methods
2.1 Subjects and MRI data
We used T1-weighted ADNI images (data used in the
preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (adni.loni.u-
cla.edu)) that have undergone image correction described at the
ADNI website. ADNI image correction steps include Gradwarp,
N3, and scaling for gradient drift – see www.loni.ucla.edu/ADNI/
Data/ADNI_Data.shtml. ADNI aims to recruit and follow 800
research participants in the 55–90 age range: approximately 200
elderly Controls, 400 people with MCI, and 200 people with AD.
The number of Control, MCI, and AD participants in our analy-
sis were &180, 300, and 120, respectively – experiment-specific
detailed descriptions will be provided in Sec. 3. We processed the
T1-weighted images as described in the supplemental Document
S1, producing new images from which we then obtained the
features (next discussed) used by our statistical classifiers.
MRI-Derived Definition of MCI-to-AD Conversion
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We chose as features the voxel intensities of a processed
RAVENS image (we describe our processing of RAVENS images
in the supplemental Document S1), a type of ‘‘volumetric density’’
image [28,29,30,31] that has been validated for voxel-based
analysis [29] and applied both to AD e.g. [4,5,13] and other
studies e.g. [32]. Of particular interest [29], supported that voxel-
based SPM statistical analysis, which we perform herein for
comparison with our methods, can be performed on RAVENS
images. For each of the three processed RAVENS tissue maps
(gray matter (GM), white matter (WM), and ventricle), to reduce
complexity for subsequent processing, we obtained a subsample by
successively skipping five voxels along each of the three
dimensions, and took as feature set the union of the three
subsampled maps. We will also report results for the case of
skipping only two voxels, rather than five.
Since high-dimensional nonlinear registration (warping) of all
individuals to a common atlas (via HAMMER [33]) is applied in
producing our features, they capture both volumetric and
morphometric brain characteristics, which is important since
individuals with AD/MCI typically exhibit brain atrophy
(affecting both volume and shape).
2.3 Classification and feature selection for high-
dimensional images
A challenge in building classifiers for medical images is the
relative paucity of available training samples, compared to the
huge dimensionality of the voxel space and, thus, to the number of
parameters in the classifier model – in general, the number of
parameters may grow at least linearly with dimensionality. In the
case of 3D images, this could imply even millions of parameter
values (e.g. one per voxel) need to be determined, based on a
training set of only a few hundred patient examples. In such cases,
classifier overfitting is likely, which can degrade generalization
(test set) accuracy. Here we will apply a linear discriminant
function (LDF) classifier with a built-in mechanism to avoid
overfitting and with design complexity that scales well with
increasing dimensionality - the support vector machine (SVM)
[34]. The choice of LDF achieving perfect separation (no
classification errors) for a given two-class training set is not
unique. The SVM, however, is the unique separating LDF that
maximizes the margin, i.e. the minimum distance to the classifier
decision boundary, over all training samples. In this sense, the
SVM maximizes separation of the two classes. For an SVM, unlike
a standard LDF, the number of model parameters is bounded by
the number of training samples, rather than being controlled by
the feature dimensionality. Since the number of samples is the
much smaller number for medical image domains, in this way the
SVM greatly mitigates overfitting. SVMs have achieved excellent
classification accuracy for numerous scientific and engineering
domains, including medical image analysis, [26,4,27].
Even though SVMs are effective at mitigating overfitting,
generalization accuracy may still be improved in some cases by
removing features that contribute little discrimination power.
Moreover, even if generalization accuracy monotonically improves
with increasing feature dimensionality, high complexity (both
computation and memory storage) of both classifier design and
class decisionmaking may outweigh small gains in accuracy
achieved by using a huge number of features. Most importantly
here, it is often useful to identify the critical subset of features
necessary for achieving accurate classification – these ‘‘markers’’
may shed light on the underlying disease mechanism. In our case,
this will help to identify prognostic brain regions, associated with
MCI conversion.
Unfortunately, there is a huge number of possible feature
subsets, with exhaustive subset evaluation practically prohibited
even for a modest number of features, M, let alone M*106.
Practical feature selection techniques are thus heuristic, with a
large range of tradeoffs between accuracy and complexity [35].
‘‘Front-end’’ (or ‘‘filtering’’) methods select features prior to
classifier training, based on evaluation of discrimination power
for individual features or small feature groups. ‘‘Wrapper’’
methods are generally more reliable, interspersing sequential
feature selection and classifier design steps, with features
sequentially selected to maximize the current subset’s joint
discrimination power. There are also embedded feature selection
methods, e.g. for SVMs, use of ‘1-regularization within the SVM
design optimization [36], in order to find ‘‘sparse’’ weight vector
solutions, which effectively eliminate many features. For wrappers,
there is greedy forward selection, with ‘‘informative’’ features
added, backward elimination, which starts from the full set and
removes features, and more complex bidirectional searches. In our
work, due to the high feature dimension, we focus on two
backward elimination wrappers that afford practical complexity: i)
the widely used recursive feature elimination algorithm (RFE)
[27], where at each step one removes the feature with least weight
magnitude in the SVM solution. RFE has been applied before to
AD [4,5,13]; ii) the recent margin-based feature elimination (MFE)
algorithm [26], which uses the same objective function (margin)
for feature elimination, one consistent with good generalization,
that the SVM uses for classifier training [34]. MFE was shown in
[26] to outperform RFE [27] and to achieve results comparable to
embedded feature selection for domains with up to 8,000 features
(gene microarray classification). Here we will also find that MFE
gives better results than RFE.
2.4 An MRI-Derived Alternative to CDR-based MCI-to-AD
Conversion
In the Introduction, we outlined our two classifier design steps
for building an automatic prognosticator for an individual with
MCI. In this section, we elaborate on these two steps and give an
illustrative example. Our AD-Control classifier, used in the first
step, is discussed in Sec. 2.4.1, and our second classifier, used to
discriminate converter-by-trajectory (CT) and nonconverter-by-
trajectory (NT) classes, is discussed in Sec. 2.4.2.
2.4.1 AD-Control classifier. For the AD training popu-
lation, we chose individual AD visit images with a CDR score of at
least 1. For the Control training population, on the other hand, we
only chose initial visits, and only those for participants who stayed
at CDR=0 throughout all their visits. Thus, we excluded Controls
with ‘‘questionable dementia’’ (i.e., CDR=0.5) at any visit. By
these choices, we sought to exclude outlier examples or even
possibly any mislabeled examples, recalling that CDR for the
majority of both AD and MCI participants is 0.5 throughout all
visits.
2.4.2 CT-NT classifier. Fig. 1 gives an illustrative example
of the phenotypical score trajectories for MCI subjects, as
described in the Introduction. A positive score is on the Control
side and a negative score is on the AD side – the x-axis represents
the AD-Control SVM’s decision boundary. Score vs. age is
plotted, with each line segment a trajectory obtained by linearly
fitting an individual’s phenotype scores (and linearly extrapolating
if there are missing visits). Nonconverters-by-CDR (N-CDR) and
converters-by-CDR (C-CDR) are illustrated in (a) and (b),
respectively. Green and black subjects are those whose fitted
trajectory stayed on the Control side and AD side, respectively,
whereas gray lines are subjects who crossed to the AD side. Thus,
by our conversion-by-trajectory definition, the green group is the
MRI-Derived Definition of MCI-to-AD Conversion
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together are the converters-by-trajectory. Subject counts for
these groups are given in the figure legends. The outlier subjects
are shown in orange – there are five, making up less than 2% of
the MCI cohort. Notice, intriguingly, from the left figure that
more than one third of all (non-orange) MCI patients (106 of 298)
are converters by trajectory and yet nonconverters according to
CDR – i.e., there is a very large percentage of patients for which
the two converter definitions disagree, with the neuroimage-based
definition indicating disease state changes that are not predicted
using the clinical, CDR-based definition. Likewise, an additional
3% of all MCI subjects (11 of 298) ‘‘defy’’ their by-CDR converter
label in that they do not reach the AD side of the decision
boundary.
Based on these trajectories, i.e. whether or not the AD side is
visited, we derive the ground-truth ‘CT’ and ‘NT’ labels for all
MCI subjects. We then build a CT-NT classifier using as input only
the image scans at initial visit. (For a small percentage of the MCI
subjects, we did not obtain the patient’s first visit. However, we did
ensure that the visit we took as the ‘‘initial visit’’ had a CDR of
0.5.)
Before continuing, we note that the reader may reasonably
wonder why, rather than our converter definition and associated
two-stage classifier design, we do not simply directly apply the
Control-AD classifier to an MCI’s baseline visit image, and declare
the patient a converter if the image is classified ‘‘AD’’ and a
nonconverter, otherwise. There are several answers to this query.
First, there is no longitudinal ground-truth for MCI subjects that
can be derived for this alternative converter definition. Thus, one
cannot evaluate this definition with respect to Desideratum 2
(generalization accuracy). Second, recall that our objective is 3-
year ahead prognosis, not diagnosis. If nearly all of the MCI
converters do actually convert at first visit, then our by-trajectory
conversion definition would in practice be equivalent to this
simpler, alternative definition. We have investigated this: from a
population of 284 MCIs, there are 159 MCI converters-by-
trajectory. Of these 159, 105 do in fact convert at first visit (an AD-
Control classifier classifies the baseline visit as ‘‘AD’’). But this
means that more than one third of MCI converters-by-trajectory
convert after the first visit, and these converters would be missed by
the simpler definition. Essentially, the difference ‘‘in practice’’
between our proposed definition, and one which simply directly
applies the Control-AD classifier to the baseline visit is quite a few
more (more than one third of the total) by-trajectory converters.
Results and Discussion
3.1 Introductory overview
In this section we will perform 1) classification experiments to
evaluate conversion-by-trajectory and conversion-by-CDR with
respect to desideratum 2; 2) additional experiments to compare the
two definitions with respect to desideratum 3; and lastly, 3)
experiments to identify prognostic brain ‘‘biomarker’’ regions.
It is important to mitigate the potential confounding effect of the
subject’s age. In our classification experiments, we mitigated in
two ways:
1) For every classifier training, each training sample in one class
was uniquely paired via ‘‘age-matching’’ with a training
sample in the other class (with age separation at most one
year).
2) For every linear-kernel SVM classifier, we separately adjusted
each feature for age prior to classification using linear fitting.
We subtracted the extrapolated line (computed only using
‘control’’ samples – for the AD-Control classifier, these are
the samples in the Control class and for the CT-NT classifier
we computed the line using only the NT samples) from the
feature’s value, for all (training and test) samples. As an aside,
we note that, given the subsequent linear SVM operation,
this linear fitting step is essentially equivalent to simply
treating age as an additional feature input to the linear SVM
classifier.
Finally, prior to building classifiers, we normalized feature
values to the [0,1] range, which is suitable for the LIBSVM
software [37] we used for training SVMs.
3.2 Experiments with voxel-based features
The test set (generalization) accuracy of the voxel-based AD-
Control classifier, built using 70 training samples per class, was
Figure 1. AD-Control SVM score trajectories for MCI subjects. (a) Nonconverters-by-CDR. (b) Converters-by-CDR.
doi:10.1371/journal.pone.0025074.g001
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classified.) This classifier, with high specificity for Controls, was
then applied to a population of MCI subjects to determine the CT
and NT subgroups.
3.2.1 Classification experiments for the MCI population.
Fig. 2(a) shows the sizes of the converter-by-CDR (C-CDR) and
nonconverter-by-CDR (N-CDR) groups within the ADNI MCI
cohort for a typical experiment in our work. Fig. 2(b) shows the
same population broken up as converters-by-trajectory (CT) and
nonconverters-by-trajectory (NT). Superimposing the two charts,
Fig.2(c)illustrates theiroverlap,where convertersbybothdefinitions
are accordingly indicated by orange. Since converters-by-CDR are
relatively scarce, we used a large majority of them (80%,i . e .3 9
individuals among the 48) for the by-CDR classifier’s training set,
with the rest (20%) put into the test set. We reiterate that a general
disadvantage of the by-CDR approach is its scarcity of converter
examples – by contrast, a more balanced number of examples is
available for by-trajectory training (at least 100, rather than 39,
training samples per class, as inFig. 2(b)). Note alsothat ifwe were to
use a ‘‘probable AD’’, rather than a by-CDR converter definition,
where converters are required to have undergone both CDR and
MMSE changes, there would necessarily be even fewer converter
examples, which makes ‘‘probable AD’’ even less attractive than by-
CDR from the standpoint of having anadequate sampleforclassifier
training and testing. This also raises the possibility of an alternative
clinically-based definition, based on a logical OR-ing of CDR-based
andMMSE-basedconversions,i.e.whereaconvertermusteitherhave
undergone CDR change or MMSEchanges (or both). One difficulty
here is how to define MMSE-based conversion. In [13] MMSE
scores were averaged over all visits in order to reduce noise. One can
accordingly then define MMSE-based conversion if a subject’s
MMSE score, averaged over all visits, falls below a given threshold.
The average MMSE score over all MCI subjects is 25.85. To assess
the number of additional cognitive score-based converters one could
obtain by considering MMSE, we varied a threshold on the average
MMSEscore,evaluatingatcutoffsof24,23,and22,andfindingthat
theadditionalnumberofconvertersdeclaredinthiswaywere55,35,
and 22, respectively. Thus, especially for an MMSE cutoff of 24, one
can obtain a significant number of extra converters using MMSE in
addition to CDR. However, it is unclear what is in fact a proper
choice for the MMSE threshold – simply choosing a threshold at 24
because this leads to more converters is somewhat arbitrary, without
a strong objective basis. Accordingly, in the sequel, for evaluating
clinically-based conversion, we will only experimentally evaluate
by-CDR conversion, as used in [4,5,13]. Specification of a princi-
pled combined CDR and MMSE-based conversion definition and
validation of such a definition is a good subject for future work.
A fair performance comparison between by-trajectory and by-
CDR classification requires: 1) using the same per-class training set
size (i.e. 39) for both by-CDR and by-trajectory training, and 2)
making the test set sizes the same for both classifiers. There are
several different ways in which the data can be partitioned into
training and test sets, consistent with these two conditions: i) we
can perform simple random selection on a class-by-class basis,
ensuring only that the two classifiers are given the same training/
test set sizes (but not the same sets) – note that this means that the
training sets for the converter and nonconverter classes of the
conversion-by-CDR classifier are randomly selected from the
yellow and white regions in Fig. 2(a), respectively, with no
consideration of trajectory-based (i.e. red/white) labeling illustrat-
ed in Fig. 2(b); ii) we can make the training sets of the two
classifiers identical rather than merely same-sized, as well as make the
test sets identical. This latter approach, though, will have some
bias because, in selecting samples for the by-trajectory classifier,
we will have to make use of knowledge of the samples’ conversion-
by-CDR status (and vice versa for the by-CDR classifier). The first
approach, on the other hand, clearly does not have this bias. As
both approaches are valid ways of dealing with by-CDR data
limitations, we will compare generalization accuracies of by-CDR
and by-trajectory classifiers under both these data selection
schemes, respectively, referring to these approaches as ‘‘random’’
and ‘‘identical’’ in the sequel.
Our training/test set selection procedure for the ‘‘identical
approach’’ is as follows. For the C-CDR-CT group (Fig. 2(c)),
randomly select 80% of the group (the yellow striped group of size
30 in Fig. 3(a)) such that a corresponding group within N-CDR
(white portion in Fig. 2(a)) can be found that is both NT and
satisfies age-matching. This corresponding group is illustrated in
Fig. 3(a) as the white striped group (of size 30), placed opposite
from the yellow striped area it is paired (matched) with. Likewise
for the C-CDR-NT group (Fig. 2(c)), randomly select 80% of the
group (the yellow striped group of size 9 in Fig. 3(a) such that a
corresponding group within N-CDR can be found that is both CT
and satisfies age-matching. This corresponding group is illustrated
in Fig. 3(a) as the white striped group (of size 9). Notice by
comparing this figure to Fig. 2(c) that the two white striped areas
are separated by the CT-NT border. We take the training set –
shared by the by-CDR and by-trajectory classifiers – to be
precisely the union of these four striped areas. (For the by-CDR
classifier, the class membership of any of these four subsets of the
training set is illustrated by the color being yellow or white in
Fig. 3(a). Likewise, for the by-trajectory classifier, class member-
ship is illustrated by red or white color in Fig. 3(b).) Subse-
quently, we take the test set – shared by the two classifiers – to be
Figure 2. A population of 298 MCI subjects in ADNI is shown here, broken up according to the two criteria discussed in Sec. 3.2.1:
(a) by-CDR criterion, (b) by-trajectory criterion; (c) overlap shown.
doi:10.1371/journal.pone.0025074.g002
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in 2) the special set of subjects shown in solid gray in Fig. 3(a) (also
shown identically in Fig. 3(b)). We exclude this ‘‘special set’’ (in
gray) from the test set so that all our experiments under the
‘‘identical approach’’ can have a shared, fixed test set (for fair
comparison with each other), including, crucially, an experiment
that will include this ‘‘special set’’ of samples in the training set. That
is, the test set is the tiled areas in Fig. 3(a) (or, identically, in
Fig. 3(b)).
Note above that some random selection is being employed in
choosing the training/test sets even in the ‘‘identical approach’’
(whereas, in the ‘‘random approach’’ the selection is completely
random). Thus, for both approaches, the accuracy of performance
comparison will benefit from averaging accuracy results over
multiple training/test split ‘‘trials’’, where the training and test sets
will vary from trial to trial based on the random selection that is
built into the data selection procedure (for both the ‘‘random’’ and
‘‘identical’’ approaches). This essentially amounts to a bootstrap
procedure, which aims to work with a finite (limited) amount of
data and, at the same time, both build accurate models and
accurately assess the model’s generalization accuracy [38]. Results
averaged across 10 trials are given in Table 1 for a linear-kernel
Figure 3. Test set accuracy comparison of by-CDR and by-trajectory classification. (a) Training/test set selection for by-CDR classification.
(b) Training/test set selection for by-trajectory classification. (c) By-trajectory. Left: nonconverters; Right: converters. (d) By-CDR. Left: nonconverters;
Right: converters.
doi:10.1371/journal.pone.0025074.g003
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those in Table 1, we used SVM classifiers that were built by
employing the common approach of bootstrap-based validation
for selecting the classifier’s (trial’s) hyperparameter values [26]);
m+s notation is used to indicate the mean m and standard
deviation s of quantities across the trials, which are shown
rounded up. Note that by-trajectory’s generalization performance
is as high as 0.83, whereas by-CDR’s generalization performance
is very poor – as poor as random guessing (see 0.5 and 0.56 table
values) – due mainly to poor performance on nonconverters-by-CDR.
Fig. 3(c) and Fig. 3(d) show by-trajectory and by-CDR results,
respectively, for one of the 10 trials (for the ‘‘random approach’’),
with each bar indicating distance to the classification boundary for
an MCI subject in a test population of size 88 and nonconverters/
converters shown in left/right figures, respectively. Positive/
negative distance means nonconverter/converter side of the
boundary, respectively. Among the 88 subjects, by-trajectory
correctly classified 79 whereas by-CDR correctly classified only
40.
Recently, similarly poor by-CDR classification performance was
also reported in [4], where it was found that the majority of (by-
CDR) nonconverters ‘‘had sharply positive SPARE-AD scores
indicating significant atrophy similar to AD patients’’. Since the
SPARE-AD score is produced by a classifier that was trained to
discriminate Control and AD patients [32,16], this comment and
associated results are consistent both with our conjecture in the
Introduction and our above histogram results, which suggest that
there may be a significant number of patients undergoing
physiological brain changes consistent with conversion, yet without
clinical manifestation.
The results above indicate that the conversion-by-CDR
definition’s two classes are not well-discriminated, and thus,
clinical usefulness of this definition for our prognostic Aim is
expected to be poor. The much greater generalization accuracy of
the by-trajectory definition (coupled with its inherent plausibility as
a conversion definition) indicates its greater utility.
Increasing the By-Trajectory Image-Based Feature Resolution: In a
separate experiment, we evaluated using one of 27 subsamples
(rather than one of 216 subsamples), i.e. a *10-fold increase in the
number of (voxel-based) features, and found that the by-trajectory
generalization accuracy rose to 0.91 in the ‘‘random’’ case. We
then tried building 27 separate by-converter classifiers, one for every
1/27th subsample (thus effectively using the whole 3D image),
with majority-based voting used to combine the 27 decisions. This
ensemble scheme again achieved 0.91 accuracy, i.e. there was no
further accuracy benefit beyond that from a *10-fold increase in
the number of voxel features.
Increasing the By-Trajectory Training Set Size: Note that the
converter-by-CDR sample scarcity and class-balancing (via age-
matching) in the experiments above had the effect of artificially
limiting the by-trajectory classifier training set size. Next we
investigated how much the generalization accuracy of by-
trajectory classification improves when this limitation is removed.
The tiled areas in Figures 3(a) and 3(b) are identical, illustrating
that in this new experiment (Fig. 4 and Table 2) we used the same
test set as previously, for fairness of comparison. However, as
indicated by differences in the total striped area between these two
charts, we now make the training set much larger than previously.
Specifically, for the ‘‘identical’’ case, we used the previous 10 trials
but simply augmented a trial’s training set with the two large,
previously-excluded gray sets, shown in Fig. 3(b), with size 60, as
these two sets do age-match each other. The results, averaged
across the 10 trials, are given in Table 2. Notice in this figure the
now larger per-class training size (on average &100 rather than
39), and that the random approach uses this size as well. The by-
trajectory results in Table 2 indicate that accuracy improved from
0:78+0:02 (Table 1) to 0:84+0:02 for the ‘‘identical approach’’,
and modestly worsened for the ‘‘random approach’’ (from
0:83+0:05 to 0:82+0:01).
A Definition Based on Both Neuroimaging and Clinical Change: We now
consider a third definition of conversion that combines the first
two definitions as follows. Let ‘‘converters’’ consist of individuals
who converted either by-trajectory or by-CDR (non-white areas
in Fig. 2(c)), with the ‘‘nonconverter’’ class consisting of the
remaining MCI individuals (white area). We give two points of
view on this new definition, ‘‘conversion-by-union’’. First, despite
the disadvantages with CDR and MMSE pointed out in sections 1
and 2 of this paper, our strictly neuroimaging-based by-trajectory
definition is not using any clinical information in defining the
phenotype, i.e. psychological effects are not being taken into
account. Second, this ‘‘union’’ definition is more inclusive in
defining an MCI subpopulation at risk, which may benefit from
early treatment or diagnostic testing. While from that perspective
the new definition is reasonable, the fact that grouping individuals
by CDR has a role in this definition may be its disadvantage,
considering that by-CDR classification was previously shown to
perform not much better than random guessing. Results, averaged
across the same 10 trials used in Fig. 3, are given in Table 3 and
indicate that conversion-by-union generalizes somewhat worse
than conversion-by-trajectory. Note that ‘‘by-union’’ is, by
definition, an instance of the ‘‘identical approach’’. To ensure
fairness of comparison with the by-trajectory definition of
conversion, our test sets, and training set sizes, in these two cases
were identical. In fact, we chose the by-union training set to be as
Table 1. Test set accuracy comparison of by-CDR and by-trajectory classification: Average test set classification accuracy using all
11,293 features.
Sample Classifier Test set
selection Converters Nonconverters Overall
Count Accuracy Count Accuracy accuracy
Random By-trajectory 46+10 :81+0:06 45+10 :84+0:05 0:83+0:05
approach By-CDR 9+10 :79+0:07 82+20 :47+0:04 0:50+0:04
Identical By-trajectory 45+10 :78+0:04 47+20 :78+0:04 0:78+0:02
approach By-CDR 9+10 :74+0:11 82+20 :54+0:04 0:56+0:04
doi:10.1371/journal.pone.0025074.t001
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Fig. 3(b) (which represents a trial example), the by-union training
set was chosen to include 1) the two large striped groups (red and
white); 2) the small ‘‘special’’ gray group (of size seven in this trial
example) and its age-matched counterpart within small white-
striped group, and; 3) a subset of the second small ‘‘special’’ gray
group (two of five individuals in this trial example) and its age-
matched counterpart within the small red-striped group. We do
not further evaluate ‘‘conversion-by-union’’ here. We do, however,
identify ‘‘optimal’’ definition of a multidimensional phenotype and
associated conversion, based on neuroimaging, multiple cognitive
measures ( e.g., CDR and MMSE), genetic markers, and CSF
markers (if routinely measured) as a good direction for future work.
3.2.2 Validation on Known AD Conversion Biomark-
ers. To validate the proposed conversion definitions with respect
to desideratum 3, we performed correlation tests on
the MCI population between the binary class variable
C[f0~no conversion,1 ~conversiong and known AD
conversion biomarkers consisting of: 1) volume in reported AD-
affected regions (Table 2 in [11]), which we measured for each
individual’s final-visit MRI (As discussed in the supplemental
Document S1, we measured normalized region volume. Note also
that our regions are defined based on the atlas (Atlas2) we used. The
correspondence between the regions in [11] and our defined regions is
given in Table 4. Finally, note that a subject’s final visit is not always
the sixth visit.); 2) the following CSF-based markers, as considered
previously in [12]: tau, p-tau, Ab1-42; and 3) the clinical MMSE
measure. The stronger the correlation, the more accurately the
biomarker is predicted from the class variable and the greater the
separation between the biomarker histograms, conditioned on the two
classes. In particular, we would expect that a good converter definition
should have statistically significant correlation between its class
variable and region volume at final visit for known marker regions
such as the hippocampus. We note, however, that for measuring
correlation between the by-trajectory class label C and the final-visit
MRI-derived region volume biomarkers, some care is required to
avoid statistical bias. In particular, note that the by-trajectory label is
obtained by applying the Control-AD classifier to each visit’s MRI,
with conversion declared if any of the visits (including the final one) is
classified as ‘‘AD’’. Since the final visit is also used to measure the
region volume biomarkers we will use to validate the by-trajectory
labels, this ‘‘dual use’’ of the final visit would be a source of bias. There
are 22 MCI subjects that by-trajectory convert only at the final visit.
To avoid bias in validating the by-trajectory approach, we excluded
these 22 subjects from brain region-volume based statistical validation
of the by-trajectory definition. The full MCI population (including
these 22 subjects) was used in all our other validation testing.
Before presenting correlation test results, we first illustrate in
Fig. 5 the increased separation of the histograms of hippocampus
volume for the converter and nonconverter groups in the by-
trajectory case, compared with by-CDR. Next, we performed
comprehensive statistical tests for a number of suggested AD
biomarkers. The R statistical computing package was used to
perform all tests with statistical significance set at the 0.05 level. In
Table 5a, the correlation coefficients for by-trajectory and by-
CDR are shown for each biomarker, along with their associated p-
values [39]. Note that for 10 out of 14 brain regions, the
correlation with by-trajectory is greater than the correlation with
by-CDR (in bold), with by-trajectory meeting the significance
threshold in 9 of these 10 regions. Further, for only two of the
remaining four biomarkers - posterior cingulate and the clinical
MMSE measure - does the correlation with by-CDR meet the
significance threshold. Most notably, well-established markers for
AD such as the hippocampus, lateral ventricles, and inferior
parietal exhibited strong correlation with the by-trajectory
definition. To further assess statistical significance of the comparison
between by-trajectory and by-CDR correlations, we performed a
correlated correlation test [40], the appropriate test given that the same
MCI sample population (excepting 22 excluded subjects for the
by-trajectory brain region volume tests) was used in measuring
correlations for both by-CDR and by-trajectory. This test
(Table 5b) reveals that the larger correlation of by-trajectory is
statistically significant at the 0.05 level in six brain regions (in
bold), most notably the hippocampus, with a very low p-value
(2.16e-10). By contrast, conversion-by-CDR does not achieve a
statistically significant advantage for any of the brain regions, nor
with respect to MMSE.
Statistical testing results for the CSF markers are shown in
Table 6. As seen in the table, by-trajectory has larger correlation
Figure 4. Training/test set selection for by-trajectory, consid-
ering a larger training set size (98+1 per class) and 11,293
features.
doi:10.1371/journal.pone.0025074.g004
Table 2. By-trajectory average test set classification accuracy for the larger training set size (98+1 per class) and 11,293 features.
Sample Test set
selection Converters Nonconverters Overall
Count Accuracy Count Accuracy accuracy
By-trajectory Random 45+10 :77+0:01 47+20 :86+0:02 0:82+0:01
Identical 45+10 :85+0:03 47+20 :83+0:05 0:84+0:02
doi:10.1371/journal.pone.0025074.t002
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trajectory, these correlations are statistically significant. However,
the correlated correlation test did not indicate that the comparison of
correlations reached a statistically significant level. Correlations
with p-tau were comparable for the two conversion definitions.
To summarize, testing on both brain region and CSF-based
markers validates that by-trajectory is more consistent with
conversion to AD than the by-CDR definition.
3.2.3 Identification of prognostic brain ‘‘biomarker’’
regions. In the previous section, we validated conversion
definitions using established (diagnostic) AD biomarker brain
regions (with volumes measured at final visit). In this section, we
will identify key prognostic biomarker brain regions (from the baseline
visit image) via supervised feature selection, aiming first to identify
the ‘‘essential’’ subset of voxel features, i.e. the voxels (at initial
visit) necessary for our classifier to well-discriminate the CT and
NT classes. The brain regions (consistent with a registered brain
atlas) within which these select voxels principally reside then
identify our prognostic brain biomarker regions. Similarly, we will
identify diagnostic regions, critical for discriminating between AD
and Control subjects (using our AD-Control classifier). In both
cases, the accuracy of the selected brain region biomarkers rests
heavily on the accuracy of the supervised feature selection
algorithm we employ. In Figure 6, we compare MFE and RFE
feature elimination (i.e. feature selection via feature elimination)
for both Control-AD classification and for CT-NT classification
(for one representative, example trial). The curves show test set
accuracy as a function of the number of retained features (which is
reduced going from right to left). Note that the ‘‘MFE/MFE-
slack’’ hybrid method [26]) outperforms RFE for both brain
classification tasks, achieving lower test set error rates, and with
much fewer retained features. The circle, determined without use
of the test set based on the rule in [26], marks the point at which
we stopped eliminating features by MFE, thus determining the
(trial’s) retained voxel set. This MFE-RFE comparison (and the
previous comparison in [26]) supports our use of MFE to
determine brain biomarkers.
To relate the retained voxel set to anatomic regions in the brain,
we overlaid the retained voxel set onto a registered atlas space. For
CT-NT classification, to improve robustness, the final voxel set
was formed from the union of the retained voxel sets from each of
ten feature elimination trials (each using a different, randomly
selected training sample subset). For AD-Control classification, the
final voxel set came from a single trial (the only trial, from which
the 10 CT-NT trials stemmed). For each of these two cases,
overlaying the final voxel set onto the co-registered atlas (Atlas2,
defined in the supplemental Document S1) yielded between
70–80 anatomic regions. For data interpretation purposes, we then
identified a subset of (biomarker) regions using the following
procedure. First, for each brain region, we measured the
percentage of the region’s voxels that are retained, sorted these
percentages, and then plotted them. As shown in Fig. 7(a), the
resulting curve for the AD-Control case has a distinct knee, which
we thus used as a threshold (0.125) to select the final, retained
Table 3. Average test set accuracy of by-union classification for 39+1 per-class training samples and 11,293 features.
Sample Test set
selection Converters Nonconverters Overall
Count Accuracy Count Accuracy accuracy
By-union Identical 48+10 :78+0:05 44+20 :75+0:06 0:77+0:03
doi:10.1371/journal.pone.0025074.t003
Table 4. Correspondence between the regions in [11] (left)
(except ‘‘Total GM’’ and ‘‘Total WM’’) and our defined regions
(right).
Entorhinal cortex Entorhinal cortex left/right
Fusiform gyrus Lateral occipitotemporal gyrus right/left
Hippocampus Hippocampal formation right/left
Inferior parietal GM Supramarginal gyrus left/right, Angular gyrus right/left
Lateral orbitofrontal GM Lateral front-orbital gyrus right/left
Lateral ventricles Lateral ventricle left/right
Medial orbitofrontal GM Medial front-orbital gyrus right/left
Parahippocampal gyrus Parahippocampal gyrus right/left
Posterior cingulate Cingulate region left/right
Precentral GM Precentral gyrus right/left
Superior frontal GM Superior frontal gyrus left/right
Superior temporal GM Superior temporal gyrus right/left
doi:10.1371/journal.pone.0025074.t004
Figure 5. For the hippocampus, by-trajectory (red) has larger
histogram separation between converter (dashed line) and
nonconverter (solid line) groups than by-CDR (blue). To illustrate
this more clearly, also shown is the Gaussian curve for each of these
four subject groups (plotted based on group mean (m) and standard
deviation (s) indicated in the figure legend with the same 0.001 scaling
as the x-axis).
doi:10.1371/journal.pone.0025074.g005
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for the CT-NT curve, shown in Fig. 7(b). This choice of threshold
yields a reasonable number of regions – 19 for the CT-NT
(prognostic) case and 21 for the AD-Control (diagnostic) case.
The resulting sets of identified prognostic and diagnostic
biomarkers are given in Table 7, along with their intersection.
The diagnostic markers in the table include the majority of the
known brain regions in the medial temporal lobe involved in AD
pathology. For example, hippocampus atrophy and lateral
ventricle enlargement, particularly in its anterior aspects of the
temporal horn, are considered the most prominent diagnostic
markers for AD. Entorhinal cortical regions, including the
perirhinal cortex, are presumably the earliest sites of degeneration
[41]. Thus, independent identification by our AD-control classifier
of known AD diagnostic biomarkers establishes a reasonable basis
for applying the same approach to identify prognostic biomarkers.
The brain regions listed as CT-NT prognostic markers include
most known AD diagnostic markers (including 8 of the 12 regions
from [11] (marked by *), 4 of which are also diagnostic markers),
indicating that some AD-linked pathological changes in these
brain regions already occurred and remained active in a subset of
MCI subjects who likely progress to AD rapidly. Conversely, the
brain areas appearing only on the prognostic marker list are likely
the most active areas of degeneration during this stage of
progression to dementia. These structures tend to be the brain
regions further away from the entorhinal cortex onto the parietal
(Supramarginal gyrus, Precuneus) and temporal cortex (Superior
temporal gyrus and Middle temporal gyrus) regions. All the brain
structures listed in the table are known to be involved in AD
[41,42,43]. Thus, the markers in Table 7 suggest an interesting
anatomic pattern of trajectory for MCI conversion to AD which
conforms with the Brak and Brak hypothesis and previous imaging
Table 5. Correlation coefficients and associated p-values: (a) Correlation test results; (b) Correlated correlation test results for each
of the regions in (a).
(a) (b)
By-trajectory By-CDR
Correlation P-value Correlation P-value P-value
Biomarker coefficient coefficient
Entorhinal cortex 0.180 3.14E-03 0.054 0.382 0.092
Fusiform gyrus 0.262 1.45E-05 0.157 0.010 0.154
Hippocampus 0.645 2.00E-16 0.245 4.99E-05 2.16E-10
Inferior parietal GM 0.249 3.72E-05 0.097 0.112 0.042
Lateral orbitofrontal GM 0.064 0.300 0.113 0.064 0.507
Lateral ventricles 0.452 6.76E-15 0.194 0.001 2.18E-04
Medial orbitofrontal GM 0.083 0.173 0.137 0.025 0.476
Parahippocampal gyrus 0.311 2.09E-07 0.063 0.305 7.75E-04
Posterior cingulate 0.026 0.666 0.164 0.007 0.067
Precentral GM 0.055 0.372 0.089 0.145 0.647
Superior frontal GM 0.240 7.37E-05 0.116 0.057 0.096
Superior temporal GM 0.325 4.99E-08 0.170 0.005 0.003
Total GM 0.404 6.34E-12 0.260 1.60E-05 0.039
Total WM 0.102 0.094 0.066 0.282 0.628
MMSE 0.343 8.16E-09 0.438 5.84E-14 0.159
Statistically significant results are shown in bold.
doi:10.1371/journal.pone.0025074.t005
Table 6. Correlation coefficients and associated p-values: (a) Correlation test results; (b) Correlated correlation test results for each
of the CSF biomarkers in (a).
(a) (b)
By-trajectory By-CDR
Correlation P-value Correlation P-value P-value
CSF Biomarker coefficient coefficient
Tau 0.169 0.0457 0.119 0.159 0.624
Ptau-181 0.159 0.0604 0.153 0.0698 0.957
Ab42 0.255 2.25E-3 0.092 0.278 0.104
Statistically significant results are shown in bold.
doi:10.1371/journal.pone.0025074.t006
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our MFE-based procedure in Table 7 may be viewed as ‘‘putative’’
prognostic markers, and may warrant further investigation.
Finally, we note that we have used a particular criterion
(percentage of a region’s voxels that are retained) to identify
biomarker regions, starting from MFE-retained voxels. While our
identified regions are plausible, it is possible that other (equally
plausible) criteria may produce different biomarker region results.
Thus, the biomarkers we identify should be viewed as anecdotal,
identifying regions that figure prominently in our classifier’s
decisionmaking and also potentially assisting researchers in
forming hypotheses about MCI-to-AD disease progression.
However, we do not view the identified regions as definitive.
3.2.4 Comparison with an SPM-based biomarker
identification approach. In the previous section, we used
MFE to identify voxels as biomarkers for the CT and NT classes.
Here, using the same CT-NT training and test populations, we
will alternatively identify voxel-based biomarkers using statistical
testing with SPM5 (see: [44]). Subsequently we will present a
classifier generalization accuracy comparison (where accuracy is
again measured on the previous section’s CT-NT (test) population)
for these two biomarker detection methods. We determined SPM
biomarkers as follows. The CT-NT training set population, being
age-matched, is readily suitable for a paired t-test, an appropriate
statistical test for determining SPM-identified biomarkers, i.e.
voxels that discriminate between the CT and NT groups. In
contrast with MFE’s use of only one (out of 216) RAVENS
subsamples (taken jointly from the GM, WM, ventricle maps), we
performed t-tests on whole RAVENS maps (without
subsampling), which makes the SPM-MFE comparison
Figure 6. Test set misclassification rate during the course of feature elimination for: (a) the AD-Control classifier and (b) the CT-NT
classifier.
doi:10.1371/journal.pone.0025074.g006
Figure 7. Sorted retained voxel percentages for initial regions used to select final regions (Sec. 3.2.3): (a) AD-Control; b) CT-NT.
doi:10.1371/journal.pone.0025074.g007
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as follows. First, for the GM and WM maps separately, we
found using SPM that a large portion of each of these two tissues
was statistically significant at the 0.05 level when correction for
multiple comparisons was not applied. Next, we used SPM’s
FDR-based correction for multiple comparisons – based on an
SPM FDR cluster size of 5 voxels we found that the spatial
extent of the statistically significant regions, at each of the levels
0.05, 0.01, and 0.005, was approximately a subset of the above-
mentioned spatial support found in the uncorrected case. Given
that the number of significant voxels in any of these SPM
experiments is, again due to no subsampling, much larger than
the 11,293 voxels started from in the MFE case, we simply 1)
chose as our SPM result the result for 0.01 (FDR-corrected), 2)
took from among those significant voxels the most significant
11,434 voxels in order to be able to compare MFE and SPM
for&the same number of voxels (biomarkers). To obtain the
generalization accuracy for this SPM-identified biomarker voxel
set, using the same training/test set as in the MFE experiment,
w et r a i n e da nS V Mc l a s s i f i e ra n dm e a s u r e di t sg e n e r a l i z a -
tion accuracy, which was found to be 0.76. This accuracy is
somewhat lower than the 0.8 accuracy of the previous section’s
CT-NT SVM classifier. Recalling that this comparison is
actually favorably biased towards SPM, and further noticing
the fact that MFE was able to maintain the 0.8 accuracy all
the way down to 2000 features (cf. Fig. 6(b)), this experi-
mental comparison provides another validation (beyond
t h ec o m p a r i s o nw i t hR F Eg i v e ne a r l i e r )f o rM F E - b a s e d
feature/biomarker selection, applied to brain images.
Conclusions
We have presented an automated prognosticator of MCI-to-AD
conversion based on brain morphometry derived from high
resolution ADNI MR images. The primary novel contributions of
our work are: i) casting MCI prognostication as a novel machine
learning problem lying somewhere between supervised and
unsupervised learning; ii) our proposal of a conversion definition
which, unlike previous methods, exploits both rich phenotypical
information in neuroimages and AD and control examples; iii)
correlation testing and classifier accuracy evaluations to validate
candidate conversion definitions; iv) prognostic brain region
biomarker discovery based on our conversion definition. We
demonstrated that our method achieved both better generalization
accuracy and stronger, statistically significant, correlations with
known brain region biomarkers than a predictor based on the
clinical CDR score, the approach used in several past works. Our
method also achieved higher correlation with CSF markers than
CDR-based conversion. The brain structures identified as AD-
control diagnostic markers and MCI conversion prognostic
markers well conform with known brain atrophic patterns and
progression trajectories occurring in AD-afflicted brains. While the
noisy nature of cognitive assessments, including MMSE, has been
acknowledged in past works, in future, in order to exploit all
relevant information sources, we will aim to extend our
methodology to consider multiple cognitive assessment measures,
both potentially as additional (baseline) input features and as
additional phenotypical prediction targets to our ‘‘conversion-by-
trajectory’’ labels. We may also consider alternative ways to adjust
for confounding effects of age, noting that [11] has characterized
the nonlinear dependence of age on brain region volumes. While
we have focused on the MCI subpopulation here, our system could
also potentially be used to detect, as possible misdiagnoses, subjects
diagnosed as ‘‘Control’’ who are classified as MCI converters by
our system. Finally, we may consider the important, allied problem
of Control-to-MCI prognostication.
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Table 7. Brain regions identified as biomarkers using voxel-based features and MFE.
AD-Control classifier only intersection CT-NT classifier only
Amygdala left Hippocampal formation* left Superior temporal gyrus* left
Cingulate region right Hippocampal formation* right Middle temporal gyrus left
Entorhinal cortex right Entorhinal cortex* left Precuneus right
Inferior occipital gyrus right Inferior temporal gyrus right Lateral front-orbital gyrus* right
Medial occipitotemporal gyrus left Lateral occipitotemporal gyrus* right Insula right
Parahippocampal gyrus left Parahippocampal gyrus* right Supramarginal gyrus* left
Temporal lobe WM right Perirhinal cortex left Temporal lobe WM left
Temporal pole right Perirhinal cortex right Temporal pole left
Middle temporal gyrus right Medial front-orbital gyrus* left
Uncus left
doi:10.1371/journal.pone.0025074.t007
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